Important safety information
Prevenar is contraindicated in patients with a history of hypersensitivity to the active substances, to any of the excipients, or to diphtheria toxoid.
Prevenar will not protect against other Streptococcus pneumoniae serotypes than those included in the vaccine nor other micro-organisms that cause invasive disease or otitis media.
The use of Prevenar does not replace the use of 23-valent pneumococcal polysaccharide vaccines in children over 24 months of age with conditions placing them at higher risk for invasive disease due to Streptococcus pneumoniae. The interval between Prevenar and the 23-valent pneumococcal polysaccharide vaccine should not be less than 8 weeks.
As with other vaccines, the administration of Prevenar should be postponed in subjects suffering from acute moderate or severe febrile illness.
Prevenar should be administered intra-muscularly. Do not administer intravenously.
This vaccine should not be given to infants or children with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection unless the potential benefit clearly outweighs the risk of administration.
Different injectable vaccines should always be given at different injection sites.
Common and very common adverse events include injection site reactions, drowsiness, fever, irritability, restless sleep, vomiting, diarrhoea, and decreased appetite.
